Oscar P. Email & Phone Number

New York, Ny, Us

Chicago, Il, Us

Nucleai is an AI-powered image analysis and biomarker development company that transforms the way pathology data is leveraged throughout the development of novel therapies. We have built a biomarker development platform to seamlessly automate the detection and characterization of cells and tissue architecture in digital pathology slides and discover spatial histology features that predict response by combining imaging data with outcomes and genomic data.Our platform leverages real world datasets containing multi-omics data (pathology, clinical, and genomic), which are accessed through strategic partnerships with leading medical centers and healthcare providers in the U.S and Israel. Access to these vast, heterogeneous datasets provides Nucleai with the unique benefit of developing a robust, accurate, and generalizable digital pathology solution.

Hoboken, Nj, Us

Adjunct Professor of Artificial Intelligence in the Department of Chemistry & Chemical Biology in the Schaefer School of Engineering and Science at Stevens Institute of Technology.

New Rochelle, New York, Us

Editorial Board Member, Associate Editor and Reviewer for AI in Precision Oncology

Cambridge, Ma, Us

Accountable for biomarkers and diagnostics for all clinical development programs• Led strategic relationship with Roche Diagnostics and led the BeiGene/Roche JPT• Functional Head reviewer of all regulatory documents (2-3 clinical protocols per week; multiple clinical synopsis, trial reports and INDs) and representative to health authorities • Budget management & approval authority for all biomarker & diagnostics projects, up to $10 million• Managed a global team of 70+ members, with R&D sites in China and the US

Indianapolis, Indiana, Us

Accountable for translational, biomarker and diagnostics strategy for all late-stage programs• Established the TM team from inception, hiring all 8 members, defining working processes and successfully integrating it with other cross-functions in oncology.• Led reverse translational work for abemaciclib and ramucirumab summarized in 4 peer-reviewed manuscripts• Contributed as functional reviewer and domain expert in the regulatory submission of Ki67 CDx

Lawrence Township, Nj, Us

Accountable for Translational Medicine strategy of heme & ipilimumab development teams • Accountable for the Translational Medicine strategy in heme (elotuzumab, ipilimumab and nivolumab) and solid tumors (ipilimumab monotherapy)• Led the development of a diagnostic assay in Myeloma summarized in 2 peer-review publications

New York, Ny, Us

Oversaw Research & Development at Phosphorus• Led the development of eight CLIA-approved genetic tests, including lab assays (NGS, qPCR, ddPCR, Capillary Electrophoresis and Sanger Sequencing) and the accompanying bioinformatics pipelines needed to analyze data• Implemented ddPCR SMN1 assay saving $120K monthly, reducing extra confirmation tests >99%• Represented Phosphorus R&D at investors’ meetings, business development, client support and scientific conferences

Switzerland 🇨🇭 , Ch

Headed biomarker strategy in several oncology clinical programs, early and late stage• Biomarker lead in the cross-functional team that achieved FDA approval of Alectinib in ALK+ NSCLC and ALK+ IHC as CDx• Biomarker lead for Codrituzumab (GPC3), Simlukafusp alfa (FAP-IL2v) and Glofitamab (CD3-CD20)• Represented Roche as biomarker expert at CDER and CDRH FDA meeting• Successfully completed and transferred all G&G activities for 7 clinical programs from Nutley to Basel upon Nutley site closure, ensuring no delays on program timelines. • Successfully closed the Nutley G&G labs, meeting timelines in advance for reporting and documenting results, transferring biorepository samples to Basel and lab cleanup• Managed a team of 15 members

Rahway, New Jersey, Us

Bioinformatics and data integration support for target identification, target validation, pharmacogenomics and biomarkers discovery.• Supervised work that led to the successful termination of a program in inflammation before the compound entered First-In-Human, which saved the company over $1 million

Helsinki, Fi

Tenure-track position leading a group with two postdocs, one graduate student and three undergraduate students. Responsible for managing funding, grant applications, research project design and student supervision.

Phd, Molecular Biology

Msc, Biochemistry